Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2011 2
2012 2
2013 1
2018 1
2019 3
2020 1
2021 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

9 results

Results by year

Filters applied: . Clear all
Page 1
Management of patients with cancer during the COVID-19 pandemic: The Italian perspective on the second wave.
Indini A, Pinotti G, Artioli F, Aschele C, Bernardi D, Butera A, Defraia E, Fasola G, Gamucci T, Giordano M, Iaria A, Leo S, Ribecco AS, Rossetti R, Savastano C, Schena M, Silva RR, Grossi F, Blasi L. Indini A, et al. Among authors: butera a. Eur J Cancer. 2021 May;148:112-116. doi: 10.1016/j.ejca.2021.01.040. Epub 2021 Feb 25. Eur J Cancer. 2021. PMID: 33743478 Free PMC article.
DPYD*6 plays an important role in fluoropyrimidine toxicity in addition to DPYD*2A and c.2846A>T: a comprehensive analysis in 1254 patients.
Del Re M, Cinieri S, Michelucci A, Salvadori S, Loupakis F, Schirripa M, Cremolini C, Crucitta S, Barbara C, Di Leo A, Latiano TP, Pietrantonio F, Di Donato S, Simi P, Passardi A, De Braud F, Altavilla G, Zamagni C, Bordonaro R, Butera A, Maiello E, Pinto C, Falcone A, Mazzotti V, Morganti R, Danesi R. Del Re M, et al. Among authors: butera a. Pharmacogenomics J. 2019 Dec;19(6):556-563. doi: 10.1038/s41397-019-0077-1. Epub 2019 Feb 6. Pharmacogenomics J. 2019. PMID: 30723313 Free PMC article.
Eribulin mesylate use as third-line therapy in patients with metastatic breast cancer (VESPRY): a prospective, multicentre, observational study.
Adamo V, Ricciardi GRR, Giuffrida D, Scandurra G, Russo A, Blasi L, Spadaro P, Iacono C, Soto Parra HJ, Savarino A, Ferraú F, Zerilli F, Verderame F, Butera A, Santangelo C, Franchina V, Caruso M. Adamo V, et al. Among authors: butera a. Ther Adv Med Oncol. 2019 Dec 19;11:1758835919895755. doi: 10.1177/1758835919895755. eCollection 2019. Ther Adv Med Oncol. 2019. PMID: 31903098 Free PMC article.
Reactions and countermeasures of medical oncologists towards the incoming COVID-19 pandemic: a WhatsApp messenger-based report from the Italian College of Chief Medical Oncologists.
Blasi L, Bordonaro R, Borsellino N, Butera A, Caruso M, Cordio S, Liborio DC, Ferraù F, Giuffrida D, Parra HS, Spada M, Tralongo P, Valenza R, Verderame F, Vitello S, Zerilli F, Piazza D, Firenze A, Gebbia V. Blasi L, et al. Among authors: butera a. Ecancermedicalscience. 2020 May 15;14:1046. doi: 10.3332/ecancer.2020.1046. eCollection 2020. Ecancermedicalscience. 2020. PMID: 32565899 Free PMC article.
Cancer patient-centered home care: a new model for health care in oncology.
Tralongo P, Ferraù F, Borsellino N, Verderame F, Caruso M, Giuffrida D, Butera A, Gebbia V. Tralongo P, et al. Among authors: butera a. Ther Clin Risk Manag. 2011;7:387-92. doi: 10.2147/TCRM.S22119. Epub 2011 Sep 9. Ther Clin Risk Manag. 2011. PMID: 21941445 Free PMC article.
Adjuvant anastrozole versus exemestane versus letrozole, upfront or after 2 years of tamoxifen, in endocrine-sensitive breast cancer (FATA-GIM3): a randomised, phase 3 trial.
De Placido S, Gallo C, De Laurentiis M, Bisagni G, Arpino G, Sarobba MG, Riccardi F, Russo A, Del Mastro L, Cogoni AA, Cognetti F, Gori S, Foglietta J, Frassoldati A, Amoroso D, Laudadio L, Moscetti L, Montemurro F, Verusio C, Bernardo A, Lorusso V, Gravina A, Moretti G, Lauria R, Lai A, Mocerino C, Rizzo S, Nuzzo F, Carlini P, Perrone F; GIM Investigators. De Placido S, et al. Lancet Oncol. 2018 Apr;19(4):474-485. doi: 10.1016/S1470-2045(18)30116-5. Epub 2018 Feb 23. Lancet Oncol. 2018. PMID: 29482983 Clinical Trial.
Discontinuation of bevacizumab and FOLFIRI administered up to a maximum of 12 cycles as first-line therapy for metastatic colorectal cancer: a retrospective Italian study.
Rosati G, Cordio S, Aprile G, Butera A, Avallone A, Di Lucca G, De Pauli F, Parra HS, Reggiardo G, Bordonaro R. Rosati G, et al. Among authors: butera a. Invest New Drugs. 2012 Oct;30(5):1978-83. doi: 10.1007/s10637-011-9721-6. Epub 2011 Jul 19. Invest New Drugs. 2012. PMID: 21769636 Clinical Trial.